Vulnerable elderly patients and overactive bladder syndrome

Drugs and Aging

Volumn 27, Issue 9, 2010, Pages 697-713

  Kraus, Stephen R ^a   Bavendam, Tamara ^b   Brake, Tiffany ^c   Griebling, Tomas L ^d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b PFIZER INC   (United States)

^c Clinical Content and Editorial Services   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

botulinum toxin a, therapeutic use; darifenacin, therapeutic use; elderly; fesoterodine, therapeutic use; muscarinic receptor antagonists, therapeutic use; overactive bladder, treatment; oxybutynin, therapeutic use; tolterodine, therapeutic use.

Indexed keywords

BOTULINUM TOXIN A; CHOLINESTERASE INHIBITOR; DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONSTIPATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FRAIL ELDERLY; GERIATRIC PATIENT; GERIATRICS; HUMAN; LUMBOSACRAL PLEXUS; MEDICAL RESEARCH; MICTURITION; MORTALITY; NERVE STIMULATION; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; BEHAVIOR THERAPY; EXERCISE THERAPY; FRAIL ELDERLY; HUMANS; MUSCARINIC ANTAGONISTS; SYNDROME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 77956301174     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11539020-000000000-00000     Document Type: Review

References (126)

1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29 (1): 4-20
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 Jan; 61 (1): 37-49
3. Nuotio M, Tammela TL, Luukkaala T, et al. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res 2002 Oct; 14 (5): 412-419
4. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): 574-579
5. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008 Jun; 101 (11): 1388-1395
6. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511-519
7. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 Jul-Aug; 7 (4): 455-463
8. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010 Mar; 75 (3): 526-532, 532 e1-18
9. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 Dec; 50 (6): 1306-1315
10. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 Jun; 87 (9): 760-766
11. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327-336
12. World Health Organization. 1998 World Health Report - health in the 21st century: a vision for all. Geneva: World Health Organization, 1998
13. National Center for Health Statistics. Health, United States, 2007, with chartbook on trends in the health of Americans. Hyattsville (MD): National Center for Health Statistics, 2007. Report No.: Library of Congress Catalog Number 76-641496
14. Federal Interagency Forum on Aging-Related Statistics. Older Americans 2008: key indicators of well-being. Washington, DC: Federal Interagency Forum on Aging- Related Statistics, 2008 Mar
15. Population ageing and development: operational challenges in developing countries (number 5). New York (NY): United Nations Population Fund, 2002
16. Gao S, Hendrie HC, Hall KS, et al. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998 Sep; 55 (9): 809-815
17. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 1999 Oct; 10 (200): 1-203
18. Van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998 May; 51 (5): 367-375
19. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002 Nov 11; 162 (20): 2269-2276
20. Knutson T, Edlund C, Fall M, et al. BPH with coexisting overactive bladder dysfunction: an everyday urological dilemma. Neurourol Urodyn 2001; 20 (3): 237-247
21. Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997 Apr; 89 (4): 501-506
22. Melville JL, Katon W, Delaney K, et al. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005 Mar 14; 165 (5): 537-542
23. Diokno AC, Brock BM, Brown MB, et al. Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol 1986 Nov; 136 (5): 1022-1025
24. Song HJ, Bae JM. Prevalence of urinary incontinence and lower urinary tract symptoms for community-dwelling elderly 85 years of age and older. J Wound Ostomy Continence Nurs 2007 Sep-Oct; 34 (5): 535-541
25. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001 Dec; 49 (12): 1691-1699
26. Min LC, Elliott MN, Wenger NS, et al. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J AmGeriatr Soc 2006 Mar; 54 (3): 507-511
27. Wilson JF. Frailty, and its dangerous effects, might be preventable. Ann Intern Med 2004 Sep 21; 141 (6): 489-492
28. Gill TM, Gahbauer EA, Allore HG, et al. Transitions between frailty states among community-living older persons. Arch Intern Med 2006 Feb 27; 166 (4): 418-423
29. Nuotio M, Tammela TL, Luukkaala T, et al. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. J Gerontol A Biol Sci Med Sci 2003 Aug; 58 (8): 756-762
30. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000 Jul; 48 (7): 721-725
31. Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992 Dec; 40 (12): 1217-1220
32. Jensen J, Lundin-Olsson L, Nyberg L, et al. Falls among frail older people in residential care. Scand J Public Health 2002; 30 (1): 54-61
33. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. Aging (Milano) 1991 Jun; 3 (2): 161-170
34. Charach G, Greenstein A, Rabinovich P, et al. Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 2001 Mar-Apr; 47 (2): 72-76
35. Lawrence JM, Lukacz ES,Nager CW, et al. Prevalence and co-occurrence of pelvic floor disorders in communitydwelling women. Obstet Gynecol 2008 Mar; 111 (3): 678-685
36. Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int. Epub 2010 Jun 29
37. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am JManag Care 2001 Mar; 7 (2 Suppl.): S62-75
38. Cisternas MG, Foreman AJ,Marshall TS, et al. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Curr Med Res Opin 2009 Apr; 25 (4): 911-919
39. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003 Jun; 61 (6): 1123-1128
40. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004 Mar; 63 (3): 461-465
41. Subak LL, Brown JS, Kraus SR, et al. The costs of urinary incontinence for women. Obstet Gynecol 2006 Apr; 107 (4): 908-916
42. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I, non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology - in collaboration with the Society of Geriatric Cardiology. Circulation 2007 May 15; 115 (19): 2549-2569
43. DuBeau C, Kuchel GA, Johnson T, et al. Incontinence in the frail elderly. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. 4th ed. Paris: Editions 21, for Health Publication Ltd, 2009: 963-1024
44. Yoshida M, Miyamae K, Iwashita H, et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004; 63 (3 Suppl. 1): 17-23
45. Griffiths D, Tadic SD, Schaefer W, et al. Cerebral control of the bladder in normal and urge-incontinent women. Neuroimage 2007 Aug 1; 37 (1): 1-7
46. Elbadawi A, Diokno AC, Millard RJ. The aging bladder: morphology and urodynamics. World J Urol 1998; 16 Suppl. 1: S10-34
47. McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006 Jan; 35 (1): 16-24
48. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004 Jun; 56 (2): 163-184
49. Modi A, Weiner M, Craig BA, et al. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc 2009 Jul; 57 (7): 1238-1244
50. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000 Aug 12; 356 (9229): 568
51. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimers disease associated with Downs syndrome [letter]. Am J Psychiatry 1999 Sep; 156 (9): 1470
52. Sink KM, Thomas 3rd J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008 May; 56 (5): 847-853
53. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004 Jan; 57 (1): 6-14
54. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged - the Index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914-919
55. Lawton MP, Brody EM. Assessment of older people: selfmaintaining and instrumental activities of daily living. Gerontologist 1969; 9 (3): 179-86\
56. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998 Feb 25; 279 (8): 585-592
57. Reuben DB, Rubenstein LV, Hirsch SH, et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992 Dec; 93 (6): 663-669
58. Guralnik JM, LaCroix AZ, Branch LG, et al. Morbidity and disability in older persons in the years prior to death. Am J Public Health 1991 Apr; 81 (4): 443-447
59. Carr LK. Overactive bladder. Can J Urol 2008 Aug; 15 Suppl. 1: 32-6; discussion 6
60. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001 Jun; 49 (6): 700-705
61. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007 Oct; 23 (10): 2347-2358
62. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002 May; 50 (5): 799-807
63. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005 Sep; 48 (3): 471-477
64. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006 Mar; 4 (1): 14-24
65. Griebling TL, Kraus SR, Richter HE, et al. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009 Aug; 63 (8): 1198-1204
66. Kraus SR, Ruiz-Cerda JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology. In press
67. Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007 Nov; 23 (11): 2697-2704
68. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998Dec 16; 280 (23): 1995-2000
69. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001 May; 165 (5): 1452-1456
70. Ouslander JG, Maloney C, Grasela TH, et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2001 Sep-Oct; 2 (5): 207-214
71. Michel MC, Schneider T, Krege S, et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002 Sep; 168 (3): 1027-1031
72. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum 1989 Jan; 32 (1): 1-8
73. Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5
74. Leung FW. Etiologic factors of chronic constipation: reviewof the scientific evidence. Dig Dis Sci 2007 Feb; 52 (2): 313-316
75. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. AmJ Psychiatry 1992 Oct; 149 (10): 1393-1394
76. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332 (7539): 455-459
77. Blazer 2nd DG, Federspiel CF, Ray WA, et al. The risk of anticholinergic toxicity in the elderly: a study ofprescribing practices in two populations. J Gerontol 1983 Feb; 38 (1): 31-35
78. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003 Feb; 60 (2): 198-203
79. Tsao J, Shah R, Leurgans S, et al. Impaired cognition in normal individuals using medications with anticholinergic activity occurs following several years. American Academy of Neurology 60th Anniversary Annual Meeting; 2008 Apr 12-18; Chicago (IL)
80. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998 Feb; 46 (1): 8-13
81. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use.NEngl J Med 2003 Dec 4; 349 (23): 2274-2275
82. Williams SG, Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 2004 Nov; 55 (11): 1318-1319
83. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol 2003 May; 60 (5): 771-773
84. Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 2007 Aug; 197 (2): e8
85. Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23 (6): 395-404
86. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005 Nov; 96 (7): 1055-1062
87. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008 Nov; 62 (11): 1792-1800
88. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006 Aug; 50 (2): 317-326
89. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005 Feb; 173 (2): 493-498
90. Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged 50 years. BJU Int 2005 Feb; 95 (3): 346-349
91. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004 Dec; 5 (6): 423-426
92. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008 May; 56 (5): 862-870
93. Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009; 283 (1-2): 99-106
94. Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005 Apr; 144 (8): 1089-1099
95. Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drugdrug interaction potential.Geriatrics 2007 May; 62 (5): 15-24
96. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999 Nov; 33 (11): 1173-1176
97. Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging 2008; 25 (10): 871-877
98. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009 Aug; 63 (8): 1177-1191
99. Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002 Nov 13; 288 (18): 2293-2299
100. Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991 Feb 6; 265 (5): 609-613
101. Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2000; (2): CD002113
102. Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebocontrolled trial. J Am Geriatr Soc 1995 Jun; 43 (6): 610-617
103. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000 Apr; 48 (4): 370-374
104. Burgio KL, Kraus SR,Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008 Aug 5; 149 (3): 161-169
105. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007 Feb; 99 (2): 247-262
106. White WM, Pickens RB, Doggweiler R, et al. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 2008; 180 (6): 2522-2526
107. Kaplan SA, Wein AJ, Staskin DR, et al. Urinary retention and post-void residual urine inmen: separating truth from tradition. J Urol 2008 Jul; 180 (1): 47-54
108. Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. JUrol 2009 Apr; 181 (4): 1773-1778
109. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008 Jul; 180 (1): 217-222
110. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006 Jul; 176 (1): 177-185
111. Rule AD, Jacobson DJ, McGree ME, et al. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 2005 Oct; 174 (4 Pt 1): 1317-21; discussion 21-2; author reply 22
112. Blok BF, Groen J, Bosch JL, et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 2006 Dec; 98 (6): 1238-1243
113. Amundsen CL,Romero AA, JamisonMG, et al. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology 2005 Oct; 66 (4): 746-750
114. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006 Mar; 175 (3 Pt 1): 835-841
115. McMurdo ME, Witham MD, Gillespie ND. Including older people in clinical research. BMJ 2005 Nov 5; 331 (7524): 1036-1037
116. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995 Jul;24 (4): 287-291
117. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003 Jan 25; 326 (7382): 196
118. Spinewine A, Swine C, Dhillon S, et al. Appropriateness of use of medicines in elderly inpatients: qualitative study. BMJ 2005 Oct 22; 331 (7522): 935
119. Siu LL. Clinical trials in the elderly: a concept comes of age. N Engl J Med 2007 Apr 12; 356 (15): 1575-1576
120. Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol 2008; 10 (2): 92-98
121. Hamad RA, Dmochowski RR, Dahl NV, et al. Quality of life and safety with transdermal oxybutynin in patients 85 years and older with overactive bladder: results from MATRIX study [abstract no. B21]. J Am Geriatr Soc 2006; 54 (S4): S71-2
122. Resnick NM. Urinary incontinence. Lancet 1995 Jul 8; 346 (8967): 94-99
123. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul-Aug; 11 (4): 458-461
124. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007 Jul 14; 370 (9582): 173-184
125. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983 Dec; 31 (12): 721-727
126. Katz S, Downs TD, Cash HR, et al. Progress in development of the Index of ADL. Gerontologist 1970; 10 (1): 20-30